. Author manuscript; available in PMC: 2017 Sep 20.

Published in final edited form as: Eur J Pharm Sci. 2016 Jul 1;92:117–130. doi: 10.1016/j.ejps.2016.06.026

Table 2.

Demographic data and summary of dataset

	Female	Male
N^a	16	14
Weight (kg)^b	0.73 ± 0.29 (0.53–1.62)	0.86 ± 0.24 (0.61–1.4)
Height (cm)^b	32.41 ± 3.13 (27.5–41)	33.29 ± 2.12 (30–37)
PMA (weeks)^b	25.88 ± 1.75 (24–30.14)	27.18 ± 2.48 (23.14–32.42)
PNA (days)^b	7.94 ± 4.67 (1–19)	12.29 ± 11.28 (1–31)

	All subjects

Duration of study (hours)^b	78.1 ± 26.6 (22.3–104.1)
Indication for receiving morphine^a	PDA ligation (n=16), On ventilator (n=12), Abdominal distention (n=1), Tracheostomy (n=1)
Number of samples per subject^c (in total^a)	Morphine: 8 (n=206), M3G: 7 (n=193), M6G: 6 (n=167), PIPP: 9 (n=253)
Concentration range (ng/mL)^d	Morphine: 2.9–244.1, M3G: 0.3–531.9, M6G: 0.2–138.3
Morphine prior to study^a	No. of subjects (n=10)
Additional morphine doses^c (in total^a)	No. of subjects (n=16), Doses per subject: 3 (n=44), Additional blood samples (n=7)

: quantity,

: mean ± SD (range),

: median,

: range,

SD: standard deviation, PMA: postmenstrual age, PNA: postnatal age, M3G: morphine-3-glucuronide, M6G: morphine-6-glucuronide, PIPP: premature infant pain profile